Treatment of XXXX with circulating angiogenic cells.

@entity1 @entity35 @entity1184 @entity6560 @entity120 @entity8158 @entity1317
Despite advances in the treatment of @entity120 , a truly restorative therapy has not been achieved. Attention has been given to circulating angiogenic cells (CACs, also termed early endothelial progenitor cells) because of their ability to home to sites of @entity1317 and regenerate blood vessels. We studied the efficacy of @entity1 CAC therapy in the treatment of @entity120 at two different stages of disease severity. Cells were isolated from peripheral blood and administered to nude @entity35 on day 14 ("early") or day 21 ("late") after @entity6560 injection. The control group received @entity6560 but no cell treatment. Disease progression was assessed using right heart catheterization and echocardiography at multiple time points. Survival differences, @entity8158 ( @entity8158 ), and vascular @entity1184 were analyzed at the study endpoint. Quantitative PCR was performed to evaluate cell engraftment. Treatment with @entity1 CACs either at the early or late time points did not result in increased survival, and therapy did not prevent or reduce the severity of disease compared with control. Histological analysis of @entity8158 and vascular muscularization showed no benefit with therapy compared with control. No detectable signal was seen of @entity1 transcript in transplanted lungs at 14 or 21 days after cell transplant. In conclusion, CAC therapy was not associated with increased survival and did not result in either clinical or histological benefits. Future studies should be geared toward either earlier therapeutic time points with varying doses of unmodified CACs or genetically modified cells as a means of delivery of factors to the pulmonary arterial circulation.
